The Post-TRIPS Reality

A growing narrative in policy and industry circles suggests that Bangladesh’s pharmaceutical sector is heading towards a difficult transition once the TRIPS waiver for least developed countries expires in 2033. 

The concern is straightforward: After graduation from LDC status, Bangladesh will be required to fully comply with the global intellectual property regime under the World Trade Organization, particularly the enforcement of pharmaceutical product patents. 

This, it is argued, will disrupt access to active pharmaceutical ingredients (APIs), increase costs, and undermine the competitiveness of the domestic industry.

This narrative, however, often rests on an oversimplified understanding of how pharmaceutical supply chains and intellectual property systems actually function.

A closer examination suggests a more nuanced reality: Bangladesh is unlikely to face a systemic shock in its existing pharmaceutical base.

Instead, the sector will experience a structural shift -- one that affects future innovation and high-value segments far more than current generic production.

To understand this distinction, it is essential to separate perception from mechanism.

At present, Bangladesh’s pharmaceutical industry is overwhelmingly concentrated in the production of generic medicines.

These are drugs whose original patents have expired, allowing multiple manufacturers globally to produce and sell them without paying royalties to the original patent holders. 

A widely used example is Omeprazole, a proton pump inhibitor that has long been off-patent and is now produced competitively across multiple jurisdictions.

In such cases, there is no “patent fee” in any meaningful sense. The price of APIs reflects production costs, competition among suppliers, and logistics expenses -- not intellectual property rent.

This is why Bangladeshi firms are able to import large volumes of APIs at relatively low cost today. It is not because suppliers are absorbing patent costs invisibly, but because, in many cases, there is no patent protection left to enforce.

This point is crucial, because much of the confusion in the debate arises from the assumption that all pharmaceutical imports are somehow carrying embedded patent costs.

In reality, the global API market is highly segmented. A large portion of it is fully commoditized, with dozens of producers operating in countries such as China and India, where competition drives prices close to marginal cost.

There is, however, another segment of the market where intellectual property does matter. In newer, more complex, or highly innovative drugs, patents remain active.

In these cases, manufacturers must either obtain licenses from patent holders or develop alternative production processes that legally circumvent existing patents. 

This is where licensing fees, royalties, or embedded intellectual property costs may exist. But even here, these costs are typically internalized within the supply chain and reflected in the final price, rather than appearing as explicit “patent fees” to the buyer.

This dual structure -- off-patent commoditized products on one hand, and patent-protected innovative products on the other -- is central to understanding Bangladesh’s current position.

The second pillar of the debate concerns the role of LDC status. Under the TRIPS framework of the WTO, least developed countries are granted transitional flexibilities that allow them to delay the enforcement of pharmaceutical product patents.

This means that Bangladesh is not currently obligated to enforce such patents within its domestic legal system.

As a result, even if a product is patented elsewhere, Bangladeshi firms can import and use it without facing domestic legal restrictions.

This has led to the perception that Bangladesh is somehow operating outside the global intellectual property system. That interpretation is misleading.

In reality, the system remains intact, but with differentiated obligations based on development status. Suppliers in exporting countries must still comply with their own domestic patent laws. Therefore, any API exported to Bangladesh is either off-patent, produced under license, or manufactured through alternative processes that do not infringe active patents in the exporting jurisdiction.

The implication is important: Bangladesh is not receiving “free” patented technology. It is accessing products that are either no longer protected or legally cleared at the production stage. The absence of domestic enforcement simply expands the range of products that can be imported, not the legality of production in the exporting country.

The real question, therefore, is not whether suppliers are bypassing intellectual property costs, but whether Bangladesh’s policy space will meaningfully change after 2033.

Once the TRIPS transition period ends, Bangladesh will be required to fully implement pharmaceutical product patent protection. This is often interpreted as a dramatic turning point. However, its practical implications are more limited than commonly assumed.

First, it is important to distinguish between existing and future products. For drugs whose patents have already expired, nothing changes. These will continue to be produced globally as generics and imported into Bangladesh at competitive prices. The bulk of current pharmaceutical consumption in Bangladesh falls into this category. Therefore, the foundation of the industry remains intact.

Second, enforcement of patents does not automatically eliminate access. It introduces conditions. For patented products, access will depend on licensing agreements, compulsory licensing provisions under public health safeguards, or negotiated procurement arrangements. In other words, the system shifts from unrestricted use to regulated access, not from access to exclusion.

Third, and most importantly, the real impact will be concentrated in future high-value pharmaceuticals rather than existing generics. As the global pharmaceutical industry continues to innovate, new molecules and biologics will increasingly fall under strong patent protection.

In these areas, Bangladesh will face constraints unless it develops domestic capacity for innovation or secures licensing arrangements.

This is where the analogy with capital machinery becomes relevant. In machinery imports, a significant portion of the price reflects embedded technology, design, and intellectual property.

The same principle applies to patented pharmaceuticals: the cost of innovation is embedded in the product, not necessarily visible as a separate fee.

However, this analogy holds only for the patented segment of the market. It does not apply to commoditised generics, where competition eliminates monopoly rents.

Therefore, the argument that “no supplier gives technology for free” is only partially correct.

In competitive, off-patent markets, no such technology rent exists to be charged.

In contrast, in patented markets, the rent exists but is either internalised or conditional on licensing.

From this perspective, Bangladesh’s current advantage is not the absence of intellectual property costs, but its concentration in segments where such costs are minimal or non-existent. This structural positioning explains why the transition appears less threatening in the short term.

The key policy question is whether this positioning is sustainable in the long term. There is a tendency in some policy discussions to assume that because the current system functions smoothly, future adjustments will also be smooth.

This is where caution is needed. The post-2033 environment will not disrupt existing production, but it will reshape the boundaries of opportunity.

Three areas deserve attention.

First, innovation capacity. Without investment in research and development, Bangladesh will remain confined to low-value generics while missing opportunities in complex generics, biosimilars, and novel therapeutics.

Second, API self-reliance. Dependence on imported APIs is manageable in a world dominated by off-patent molecules, but becomes strategically vulnerable when patent-protected intermediates dominate future pipelines.

Third, legal and institutional readiness. Effective patent examination, licensing negotiation capacity, and use of WTO-consistent flexibilities will become increasingly important tools of economic policy.

In this context, it is misleading to describe the post-TRIPS transition as either a crisis or a non-event. It is neither. It is a reconfiguration of constraints.

To summarize, three core conclusions emerge.

First, Bangladesh is not currently benefiting from “free” patented technology. It is benefiting from a global structure in which a large share of pharmaceutical products are off-patent and competitively produced.

Second, the expiry of TRIPS transition will not eliminate access to medicines, but it will introduce legal and economic constraints in specific segments, particularly in newer and more complex drugs.

Third, the most significant impact will not be on today’s pharmaceutical base, but on the trajectory of future upgrading.

The debate, therefore, should move away from binary claims of disruption versus continuity. The reality is more subtle. Bangladesh will not experience a shock, but it will face a shift -- from a system dominated by generic competition to one where intellectual property plays a more active role in shaping market access and industrial upgrading.

The policy challenge is not to prevent this shift, but to prepare for it intelligently.